儿童中枢性性早熟的个体化动态风险预测、临床决策效用及因果效应评估:一项混合队列研究

注册号:

Registration number:

ChiCTR2600121592 

最近更新日期:

Date of Last Refreshed on:

2026-04-01 10:44:43 

注册时间:

Date of Registration:

2026-04-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

儿童中枢性性早熟的个体化动态风险预测、临床决策效用及因果效应评估:一项混合队列研究

Public title:

Individualized Dynamic Risk Prediction, Clinical Decision-Making Utility, and Causal Effect Evaluation of Central Precocious Puberty in Children: A Mixed Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

儿童中枢性性早熟的个体化动态风险预测、临床决策效用及因果效应评估:一项混合队列研究

Scientific title:

Individualized Dynamic Risk Prediction, Clinical Decision-Making Utility, and Causal Effect Evaluation of Central Precocious Puberty in Children: A Mixed Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王琳 

研究负责人:

王琳 

Applicant:

Wang Lin 

Study leader:

Wang Lin 

申请注册联系人电话:

Applicant telephone:

+86 10 85613629

研究负责人电话:

Study leader's
telephone:

+86 10 85613629

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

carolin_wang@bjmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

carolin_wang@bjmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市朝阳区雅宝路2号

研究负责人通讯地址:

中国北京市朝阳区雅宝路2号

Applicant address:

2 Yabao Road, Chaoyang District, Beijing, China

Study leader's address:

2 Yabao Road, Chaoyang District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属首都儿童医学中心

Applicant's institution:

Capital Children's Medical Center, Capital Medical University

研究负责人所在单位:

首都医科大学附属首都儿童医学中心

Affiliation of the Leader:

Capital Children's Medical Center, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SHERLL2026014

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都儿科研究所伦理委员会

Name of the ethic committee:

Ethics Committee of Capital Institute of Pediatrics

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-13 00:00:00

伦理委员会联系人:

王秋月

Contact Name of the ethic committee:

Wang Qiuyue

伦理委员会联系地址:

中国北京市朝阳区雅宝路2号

Contact Address of the ethic committee:

2 Yabao Road, Chaoyang District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 85628195

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@shouer.com.cn

研究实施负责(组长)单位:

首都医科大学附属首都儿童医学中心

Primary sponsor:

Capital Children's Medical Center, Capital Medical University

研究实施负责(组长)单位地址:

中国北京市朝阳区雅宝路2号

Primary sponsor's address:

2 Yabao Road, Chaoyang District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属首都儿童医学中心

具体地址:

中国北京市朝阳区雅宝路2号

Institution
hospital:

Capital Children's Medical Center, Capital Medical University

Address:

2 Yabao Road, Chaoyang District, Beijing, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

中枢性性早熟  

Target disease:

Central Precocious Puberty

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究旨在构建风险预测 — 因果效应 — 决策效用一体化的儿童中枢性性早熟临床决策支持框架,最终实现性早熟个体化精准治疗;通过构建并临床锚定含分性别最小重要差异的复合工具,开发并完成核心版、扩展版动态预测模型的多维度验证,依托边际结构模型、逆概率处理加权结合目标试验模拟评估不同生长激素治疗策略的个体化效应,开展初步成本 - 效用分析,最终将成果转化为在线计算器与风险 - 获益地图,为性早熟临床个体化诊疗提供科学依据与实用工具。  

Objectives of Study:

This study aims to establish an integrated clinical decision support framework of risk prediction-causal effect-decision utility for central precocious puberty (CPP) in children and ultimately achieve individualized precise treatment of CPP. Specifically, we will construct and clinically anchor the BRPI incorporating gender-specific minimal important difference (MID), develop and conduct multi-dimensional validation (internal, temporal and external validation) on the core and extended versions of dynamic prediction models, evaluate the individualized therapeutic effects of different gonadotropin-releasing hormone agonist (GnRHa) strategies based on marginal structural models (MSM), inverse probability of treatment weighting (IPTW) and the target trial emulation framework, perform a preliminary cost-utility analysis, and finally translate the research findings into an online calculator and a risk-benefit map, so as to provide scientific evidence and practical tools for the individualized diagnosis and treatment of CPP in clinical practice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.中枢器质性病变导致的CPP;
2.外周性性早熟;
3.单纯乳房早发育;
4.影响生长的重大遗传/代谢/慢性疾病;
5.既往参加干预性试验且可能影响结局者。

Exclusion criteria:

1.CPP caused by central organic lesions;
2.Peripheral precocious puberty;
3.Isolated premature thelarche;
4.Major genetic/metabolic/chronic diseases affecting growth;
5.Those who have participated in interventional trials in the past and may affect the outcomes.

研究实施时间:

Study execute time:

From 2026-03-01 00:00:00 To 2028-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2027-12-01 00:00:00

干预措施:

Interventions:

组别:

回顾性队列

样本量:

800

Group:

Retrospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

前瞻性队列

样本量:

400

Group:

Prospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属首都儿童医学中心 

单位级别:

三级甲等 

Institution
hospital:

Capital Children's Medical Center, Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

骨龄监测

指标类型:

主要指标

Outcome:

Bone age monitoring

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高增长速率

指标类型:

主要指标

Outcome:

Growth velocity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Tanner进展

指标类型:

主要指标

Outcome:

Tanner staging progression

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗响应及随访时长

指标类型:

主要指标

Outcome:

Treatment response and follow-up duration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 4 years
最大 Max age 16 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

由于研究信息涉及患儿个人隐私,因此不进行数据共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Since the research information involves the personal privacy of the sick children, data sharing is not conducted.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表以及电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-01 10:44:37